Dolutegravir twice-daily dosing in children with HIV-associated TB: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Children with HIV-associated TB have few antiretroviral therapy options. A study, published in The Lancet HIV, evaluated the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB.

To access the full study, click here.